Innovative Neonatal EEG Monitoring by NeuroBell
A notable advancement in neuromonitoring has recently emerged with the introduction of NeuroBell’s innovative seizure detection technology. This development comes amidst a dynamic landscape of progress in the field, marking a significant stride towards enhancing newborn care.
Securing €2.1 million in seed funding, NeuroBell has garnered support from various investors, including Furthr VC, Atlantic Bridge, HBAN, as well as backing from Enterprise Ireland and private stakeholders. This financial backing underscores confidence in NeuroBell’s vision and the potential impact of its advancements.
Collaborative efforts with University College Cork and the INFANT Research Centre have been pivotal in nurturing and advancing NeuroBell’s technology. Set to debut in 2025, the company’s approach to seizure detection and neonatal EEG monitoring holds promise for improving early intervention strategies and providing healthcare professionals with vital real-time insights.
Beyond its technological significance, NeuroBell’s progress reflects a commitment to enhancing patient outcomes and advancing medical science. The dedication of its team, including Mark O’Sullivan, Alison O’Shea, and Colm Murphy, has been instrumental in realizing this vision.
NeuroBell’s emergence signifies a positive step forward for neonatal care. As we look ahead to the impact of its technology, there is anticipation for its transformative effects on neuroscience and patient well-being.
At the Pediatric Academic Societies (PAS) Annual Meeting in 2022, we had the opportunity to sit down with Mark O’Sullivan, the CEO & Co-Founder of NeuroBell, and hear about this revolutionary technology. Check out the conversation below:
